aod9604 clinical trials results weight loss AOD-9604: Loss, Evidence, Safety & Legal Status This Peptide Tripled My Patients'

The evidence reality There is no robust, high-quality human outcomes literature showing that adding AOD-9604 to semaglutide or tirzepatide produces clinically meaningful additional fat loss beyond what GLP-1/GIP therapy already achieves

This prescription-strength B12 injection is typically used as a maintenance therapy and is often dosed at 1 mL once a month

This enzyme regulates the metabolism of nicotinamide while influencing cellular methylation pathways and the availability of metabolic cofactors

Some people may not enjoy the taste of liquid or dissolvable supplements

The peptides very short half-life (3 minutes) means it does not accumulate in tissues over time, reducing concerns about long-term bioaccumulation

10.1038/nrc.2017.86 72